Analysis of hepatitis C virus-positive organs in liver transplantation

Muro, Manuel; Legaz Pérez, Isabel

Publication:
Analysis of hepatitis C virus-positive organs in liver transplantation

dc.contributor.author	Muro, Manuel
dc.contributor.author	Legaz Pérez, Isabel
dc.contributor.department	Ciencias Sociosanitarias
dc.date.accessioned	2024-07-11T08:43:17Z
dc.date.available	2024-07-11T08:43:17Z
dc.date.issued	2022-09-27
dc.description	© The Author(s) 2022. This manuscript version is made available under the CC-BY-NC 4.0 license http://creativecommons.org/licenses/by-nc/4.0/. This document is the Published version of a Published Work that appeared in final form in World Journal of Hepatology. To access the final edited and published work see https://doi.org/10.4254/wjh.v14.i9.1840
dc.description.abstract	The authors of this study note that in liver transplantation (LT), the survival rates of hepatitis C virus (HCV)-positive donors and HCV-negative receivers are comparable to those of HCV-negative donors and recipients. Direct-acting antiviral (DAA) therapies have nearly 100% effectiveness in treating HCV. Between 2006 and 2016, the percentages of HCV-positive patients on the waiting list and HCV-positive LT recipients fell by 8.2 percent and 7.6 percent, respectively. Records from April 1, 2014, in which the donor and receiver were both at least 18 years old and had a positive HCV status, were the only ones eligible for the study. The analysis for this study was restricted to the first transplant recorded for each patient using a data element that documented the number of prior transplants for each recipient, although some recipients appeared multiple times in the data set. HCV-positive recipients or people with fulminant hepatic failure were the main beneficiaries of primary biliary cirrhosis among HCV-positive donors. However, there is still a reticence to use HCV-positive donor organs in HCV recipients due to clinical and ethical considerations. Similar survival rates between HCV-positive donors and recipients and HCV-negative donors and receivers illustrate the efficacy of these DAA regimens.	es
dc.format	application/pdf	es
dc.format.extent	5	es
dc.identifier.citation	World J Hepatol 2022 14(9): 1840-1843
dc.identifier.doi	https://doi.org/10.4254/wjh.v14.i9.1840
dc.identifier.issn	Electronic: 1948-5182
dc.identifier.uri	http://hdl.handle.net/10201/142984
dc.language	eng	es
dc.publisher	Baishideng Publishing Group
dc.relation	Sin financiación externa a la Universidad	es
dc.relation.publisherversion	https://www.wjgnet.com/1948-5182/full/v14/i9/1840.htm
dc.rights	info:eu-repo/semantics/openAccess	es
dc.rights	Atribución-NoComercial 4.0 Internacional	*
dc.rights.uri	http://creativecommons.org/licenses/by-nc/4.0/	*
dc.subject	Hepatitis C virus	es
dc.subject	Liver transplant	es
dc.subject	Graft survival	es
dc.subject	United network for organ sharing	es
dc.subject	Direct-acting antiviral	es
dc.title	Analysis of hepatitis C virus-positive organs in liver transplantation	es
dc.type	info:eu-repo/semantics/article	es
dspace.entity.type	Publication	es
relation.isAuthorOfPublication	b83b4b59-2d61-40f0-9108-5c6a6d158295
relation.isAuthorOfPublication.latestForDiscovery	b83b4b59-2d61-40f0-9108-5c6a6d158295